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Chronic rhinosinusitis (CRS) is a prevalent disease causing a substantial burden for 
the patient and the society. CRS is divided into CRS with (CRSwNP) and without 
nasal polyps (CRSsNP). Based on current knowledge on inflammatory markers, 
CRS can be further divided into endotypes, CRSsNP mainly being characterized 
by a neutrophilic type 1 inflammatory response and CRSwNP being characterized 
by an eosinophilic type 2 inflammation. With the increase of type 2 inflammation 
in CRSwNP patients, asthma comorbidity and relapse of disease becomes more 
frequent. In recent years, monoclonal antibodies (mAbs) directed towards the type 
2 inflammatory response have been demonstrated to be efficacious in CRSwNP. 
The overall goal of this thesis was to investigate the pathophysiology of CRS and 
to evaluate effects of novel treatments.
Paper I and II focus on biomarkers and clinical characteristics to help identify type 2 
CRSwNP. Serum periostin can, together with serum IgE and Staphylococcus aureus 
enterotoxin (SE)-IgE, identify formation of IL-5 and SE-IgE in nasal polyp tissue 
with a reasonable sensitivity and specificity. Eosinophilic blood count correlates 
poorly with inflammatory markers in nasal polyp tissue, but can, together with clini-
cal history of asthma, allergy and/or aspirin exacerbated respiratory disease, help 
identify most type 2 CRSwNP patients in a clinical setting. Furthermore, in paper 
II we show that a shift towards an increase in type 2 inflammation is seen in CRS 
over recent years in Central Europe, measurable both as an increase in inflammatory 
markers and as a shift of endotype. This shift is seen in non-asthmatic, non-allergic 
patients and is more pronounced in patients with CRSwNP than in patients with 
CRSsNP. The results also indicate that polyp formation, at least in part, is driven 
by mechanisms not directly related to the type and extent of tissue inflammation.
Paper III-V focus on novel treatment strategies. Paper III shows that treatment with 
dupilumab, a mAb directed to the IL-4Receptor a, reduces local type 2 inflam-
matory parameters in nasal secretions and nasal polyp tissue. Paper IV-V focus 
on reboot surgery. Reboot surgery appears to be favorable in terms of relapse in 
moderate to severe CRSwNP compared to conventional surgery, and it reduces 
type 2 inflammatory markers in nasal secretions, 12 months after surgery, in the 
same magnitude as dupilumab. The inflammation in CRSwNP appears to be wide-
spread, involving not only polyps but also the seemingly healthy mucosa that lines 
the sinuses, a finding that strengthen the rationale for reboot surgery. 
In summary, the described shift towards type 2 inflammation in CRS suggests that 
the disease is undergoing a continuous endotypic change towards a more severe 
state of disease. It is evident that carefully chosen biomarkers in combination with 
clinical characteristics can be used to identify type 2 CRSwNP. Reboot surgery 
is favorable compared to conventional surgery, and may, based on endotypes, as 
mAbs, be implemented in treatment for CRSwNP. 
LIST OF SCIENTIFIC PAPERS
I Jonstam K, Westman M, Holtappels G, Holweg CTJ, Bachert C. Serum 
periostin, IgE, and SE-IgE can be used as biomarkers to identify 
moderate to severe chronic rhinosinusitis with nasal polyps. J Allergy 
Clin Immunol 2017; 140:1705-8.e3.
II Jonstam K, Delemarre T, Holtappels G, Cardell L-O, Westman M, Bachert 
C. Type 2 inflammatory shift in nasal polyposis. – Manuscript  
III Jonstam K, Swanson BN, Mannent LP, Cardell LO, Tian N, Wang Y, et al. 
Dupilumab reduces local type 2 pro-inflammatory biomarkers in 
chronic rhinosinusitis with nasal polyposis. Allergy 2019; 74:743-52.
IV Alsharif S, Jonstam K, van Zele T, Gevaert P, Holtappels G, Bachert C. 
Endoscopic Sinus Surgery for Type-2 CRS wNP: An Endotype-Based 
Retrospective Study. Laryngoscope 2019.
V Jonstam K, Alsharif S, Bogaert S, Suchonos N, Holtappels G, Jae-Hyun 
Park J, Bachert C. Extensive type 2 inflammation in chronic rhinosi-
nusitis with nasal polyps is suppressed by complete sinus mucosa 




2.1 Chronic rhinosinusitis 3
2.2 Pathophysiology  3
2.3 The defence system 3
2.4 Mucosal inflammation 5





2.5 Mucosal remodeling 8
2.6 Diagnostic tools 8
2.6.1 Clinical investigation 8
2.6.2 Biomarkers 8
2.7 Treatment 9
2.7.1 Current treatment 9
2.7.2 Novel treatments 9
3 MATERIALS AND METHODS 11
3.1 Human subjects 11
3.2 Sino-nasal tissue (paper I-V) 13
3.3 Nasal secretions (paper III, V) 13
3.4 Blood samples (paper I, II, V) 13
3.5 Antibody assays 14
3.5.1 Periostin (Paper I) 14
3.5.2 Enzyme-linked immunosorbent assay – ELISA (paper III) 14
3.5.3 ImmunoCAP fluorescent enzyme immunoassay (paper I-V) 14
3.5.4 Luminex (paper I-V) 15
3.6 Statistical methods (paper I-V) 15
4 RESULTS AND COMMENTS 17
4.1 Inflammation in severe CRSwNP (paper V)   17
4.1.1 Comments  18




4.3 Endotypes and phenotypes; effect on type 2  inflammatory markers  
(paper II) 20
4.3.1 IL-5 positive and negative CRS 20
4.3.2 Comorbidities impact on type 2 markers in CRSwNP  21
4.3.3 Comments 22
4.4 Identifying type 2 inflammation in CRSwNP; clinical markers and 
biomarkers (paper I and II) 22
4.4.1 Serum periostin, IgE and SE-IgE (paper I) 23
4.4.2 Blood eosinophil count and comorbidities (paper II) 24
4.4.3 Comments 26
4.5 Novel treatments (paper III-V) 26
4.5.1 Dupilumab – effect on local inflammatory markers (paper III) 26
4.5.2 Reboot surgery (paper IV and V) 27
4.5.3 Recurrence and symptom scores (paper IV) 27









AERD Aspirin exacerbated respiratory disease
AUC Area under the concentration versus time curve
CT Computed tomography
CRS Chronic rhinosinusitis
CRSsNP Chronic rhinosinusitis without nasal polyps
CRSwNP Chronic rhinosinusitis with nasal polyps
ECP Eosinophil cationic protein
ELISA Enzyme-linked immunosorbent assay
FESS Functional endoscopic sinus surgery




IL-4Rα Interleukin-4 receptor alpha







PARC Pulmonary and activated regulatory cytokine
QoL Quality of life
RAND-36 Health related quality of life questionaire
SE Standard error
SE-IgE IgE antibodies to S. aureus enterotoxins
SNOT-22 22-item sino-nasal outcome test
Th T helper cell
1
1 AIMS
The overall aim of this thesis is to investigate the pathophysiology of CRS and to 
evaluate the effects of novel treatments.  
More specific to:
• Characterize the mucosal inflammation in CRSwNP (paper II and IV).
• Determine if the balance between type 1 and type 2 inflammation in CRS 
has changed in Central Europe during the past 8-10 years (paper II).
• Identify new biomarkers in serum and comorbidities useable for further 
endotyping CRSwNP (paper I and II).
• Assess the local treatment effect of a novel monoclonal antibody 
(dupilumab) in treatment of CRSwNP by analysing inflammatory  markers 
in nasal secretion and polyp tissue (paper III)
• Appraise the clinical effect of a new surgical technique (reboot) in con-





Chronic rhinosinusitis (CRS) is a disease involving the nose and paranasal sinuses. 
The human has 4 sets of paired sinuses, the maxillary, the frontal, the ethmoid 
and the sphenoid sinuses. CRS, according to the European Positions Paper on 
Rhinosinusitis and nasal polyps (EPOS), is defined as any inflammation in the nose 
or the paranasal sinuses with symptoms prevalent for more than 12 subsequent 
weeks. The patient shall suffer from at least two symptoms, one being either nasal 
blockage/obstruction/congestion or nasal discharge, other symptoms can be facial 
pain/pressure and reduction or loss of smell. The symptoms shall be supported 
by either endoscopic signs of nasal polyps or mucopurulent discharge/oedema in 
the middle meatus and/or CT changes within the ostiomeatal complex or sinuses1. 
CRS is a common disease, the Global Asthma and Allergy European Network 
(GA2LEN)  study reported a prevalence of 10.9% in the European population 2, a 
study in the US showed that 11.9% of the population met the criteria for CRS with 
a peak in prevalence (15.9%) in the age group 50-59 3. CRS causes a substantial 
economic burden, both on direct4 and indirect costs5, the over-all direct cost of 
CRS is estimated to $10–$13 billion per year6 in the US. CRS patients report a 
considerable impact on quality of life (QoL), both on disease specific tests7, 8 and 
on generic QoL tests. These patients experience a noticeable impact on extra-
rhinologic symptoms such as difficulty to sleep, cognitive dysfunction and overall 
productivity 9 and studies have shown that QoL scores of patients with CRS are in 
the same range or below other chronic diseases such as congestive heart failure, 
coronary artery disease and Parkinson’s disease 10. 
2.2 Pathophysiology 
During many years, the term CRS has been used for any kind of chronic inflam-
mation in the nose and sinuses, implying one homogeneous disease. Recent 
findings11, 12 have pointed to a more complex picture, with different phenotypes 
and endotypes within the CRS group, with completely different histological and 
inflammatory patterns. Phenotypes are defined as measurable or observable traits 
or characteristics; in CRS, two different phenotypes are quite easy to identify with 
an endoscope, CRS with Nasal Polyps (CRSwNP) and CRS without Nasal Polyps 
(CRSsNP). In contrast, the definition of CRS endotypes are based on specific 
pathophysiological mechanisms resulting in different inflammatory responses 12, 13. 
2.3 The defence system
The skin and the mucosa constitute the first line of defence, providing a physical 
barrier. The nose and the sinuses are covered by a mucosa consisting of three layers; 
the mucus, the epithelium with columnar ciliated respiratory epithelial cells, goblet 
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cells and basal cells, and the basement membrane14. The epithelium clears pathogens 
and particles from inhaled air by mucociliary clerance15 and produces substances 
that have anti-pathogenic effects16. When chronically exposed to pathogens, the 
epithelium secrets chemokines and cytokines to activate inflammatory pathways 
and recruit immune cells17, 18 (figure 1). The main focus of the immune system is to 
protect the body against harmful substances and pathogens. It can be divided in two 
different parts, the innate and the adaptive immune systems. The innate immune 
system consists of the cellular system which includes the actions of dendritic cells, 
monocytes, macrophages and granulocytes (eosinophils, neutrophils and basophils). 
The cellular response is activated when the pathogen evades the barrier. The innate 
immune system mediates a rapid protection against pathogens. It is activated upon 
stimulation with environmental factors including infectious agents and its response 
is rapid, within hours, and does not need to be specifically instructed. The adaptive 
immune system is slow to react but is more specific and long-lasting. It consists 
of two different types of lymphocytes, B and T cells. Naïve B and T cells circulate 
in blood and lymphoid tissue until they are activated by antigen presenting cells 
such as dendritic cells. Each naïve lymphocyte carries antigen receptors unique to 
one antigen. B-cells, when activated, differentiate into antibody secreting plasma 
cells or memory B-cells. T-cells are either cytotoxic T-cells or T helper cells (Th) 
secreting different cytokines depending on the type of Th cell (Th1, Th2, Th17)19. 
The immune system contains many control mechanisms and a disruption of these 












Figure 1: A schematic overview of the mucosal barrier in the sino-nasal tract. MCC: 
Mucociliary clearance AMPs; Anti-Microbial Peptides.
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2.4 Mucosal inflammation
The underlying inflammation differs between phenotypes, i.e. CRSwNP and 
CRSsNP, and between different regions in the world. In western Europe, CRSsNP 
is mainly a type 1 neutrophilic inflammation with elevated levels of type 1 derived 
cytokines such as Interferon-g, Interleukin (IL)-1b, IL-6, IL-8 and myeloperoxidase 
(MPO)20. On the other hand, CRSwNP in western countries, is mainly character-
ised by a type 2 inflammation, dominated by cytokines that induce an eosinophilic 
inflammation, characterized by the production of Immunoglobulin E (IgE), IL-4, 
IL-5, IL-13, Eosinophil Cationic Protein (ECP), eotaxin-2 and eotaxin-3, locally 
and systemically 21, 22. Based on inflammatory markers, 10 different clusters of CRS 
have been identified, they can be divided into 3 different endotypes, types 1 to 3. 
Type 1, clinically resembling CRSsNP in the majority of cases, has a neutrophilic 
profile, and is also referred to as non-type 2. Type 2 is IL-5 positive with a moderate 
eosinophilic inflammation, clinically resembling CRSwNP rather than CRSsNP. 
Type 3 is nearly exclusively phenotyped as CRSwNP with highly elevated levels 
of IgE, ECP and IL-5, representing the most severe form of CRSwNP with high 
prevalence of asthma comorbidity and recurrences after treatment 11. In Asia, the 
inflammatory background in CRSwNP is mainly of type 1/type 1723 with a low 
proportion of type 2 CRSwNP24. This section will focus on the type 2 inflamma-
tory markers that is the main focus of this thesis.
2.4.1 IgE 
In CRSwNP, total IgE is often highly elevated in serum and in nasal polyp tissue 
compared to CRSsNP and controls. IgE is produced by plasma cells upon Th 2 
signals, such as IL-4 and IL-13, mediating a class switch recombination to IgE 
positive cells 25; this takes place in germinal centres in secondary lymphoid tissues 
and also within the polyps 26. In a subgroup of CRSwNP patients, IgE specific to 
staphylococcal enterotoxins (SE-IgE) is found in nasal polyp tissue and in serum27. 
2.4.2 ECP
ECP is a marker of eosinophilic inflammation. It is produced by eosinophils, stored 
in secondary granules within the cell and is released when eosinophils degranulate. 
The role of ECP in inflammation is not entirely understood, but elevated levels of 
ECP have been seen not only in CRSwNP, but also in other eosinophilic inflam-
matory diseases such as asthma28 and atopic dermatitis29. ECP is thought to mirror 
the numbers of activated eosinophils in tissue and blood30 and studies imply that 
elevated levels of ECP cause epithelial damage in the nasal mucosa 20, 30. 
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2.4.3 Interleukins
Th2 cells are the major source of IL-4, but in addition, mast cells, basophils and 
eosinophils are known to produce IL-4 31. IL-4 contributes to the inflammation 
in CRSwNP in multiple ways. It binds to the IL-4 receptor a (IL-4Ra) subunit 
on T-cells, present in both IL-4R type I and type II, causing them to mature from 
naïve T0 cells into Th2 cells. IL-4 has the capability to upregulate IgE receptors 
on the cell surface of mast cells, basophils, B-lymphocytes and mononuclear 
phagocytic cells and thus to upregulate the IgE-mediated immune response. By 
its interaction with vascular cell adhesion molecule-1, IL-4 directs the migration 
of eosinophils, basophils, T lymphocytes and monocytes to areas with inflamma-
tion and IL-4 can also prevent apoptosis of T lymphocytes 32. IL-4 and IL-13 have 
structural similarities and share the same receptor, IL-4R type II, that is formed by 
the IL-4Ra and IL-13Ra subunits. IL-13 stimulates mucus hypersecretion, IgE 
production, airway hyper responsiveness and subepithelial fibrosis 33, 34. However, 
it does not promote Th2 differentiation since IL-13 receptors are not expressed on 
T-lymphocytes 32. IL-5 sources include cells that express the IL-5 receptor (IL-
5R), basophils and eosinophils, and cells that do not express the IL-5R, such as 
Th2 cells, mast cells, invariant natural killer T cells and non-B/non-T cells. IL-5 
takes part in promoting the proliferation and maturation of eosinophils in the bone 
marrow, in their migration to tissue sites and in survival of eosinophils 35. IL-5 
also causes secretion of ECP 36.  IL-5 is remarkably elevated in CRSwNP patients 
with non-allergic asthma and aspirin sensitivity 37. For a schematic overview of 












Figure 2: A schematic overview of type 2 inflammation. APC; Antigen presenting cell, 
MCH II; major histocompatibility complex class II, TCR; T-cell receptor, Th0; naïve T 




Eotaxins, a family of three different chemokines, eotaxin-1 (CCL-11), eotaxin-2 
(CCL-24) and eotaxin-3 (CCL-26) are released by a number of different cell types, 
including airway epithelial cells, when exposed to IL-4 and IL-13 38. Eotaxins 
are all potent chemotactic factors for eosinophils and are elevated in different 
kinds of eosinophilic diseases such as asthma, atopic dermatitis and CRSwNP 39. 
The effect of the eotaxins on eosinophils are similar, they all act on the CCR-3 
receptor, but their genes have different chromosomal locations 40, 41. The CCR-3 
receptor is eotaxin-specific and is expressed on eosinophils and T-lymphocytes. 
T-lymphocytes that express CCR-3 are involved in a number of different activi-
ties, they produce and secrete Th2-cytokines that prime and prolong survival of 
eosinophils 39, 42. Eotaxins are also involved in mediating transepithelial eosinophil 
migration 43-45 and eotaxin-3 has been identified as the most dominant recruiter of 
eosinophils in asthma 46. 
2.4.5 Periostin
Periostin is a member of the faciclin family, an extracellular matrix protein of 
90kDa involved in the regulation of collagen deposition and fibrosis. Elevated 
levels of periostin have been associated with angiogenesis, re-entry into the cell 
cycle and with accelerated cell growth and periostin is strongly expressed in 
collagen rich fibrous connective tissue47, 48. The POSTN gene is responsible for 
periostin production, and the production is induced by the Th2 cytokines IL-4 and 
IL-1349. The last couple of years periostin has been suggested as a good marker 
of eosinophilia/Th2 inflammation 50, 51. In asthmatic patients periostin is increased 
in sputum, serum and in airway epithelial cells, and is thought to play a role in 
airway remodelling49, 51, 52. Serum periostin has also been shown to predict clinical 
response to two types of monoclonal antibody (mAb) treatments (lebrikizumab 
and omalizumab), targeting the type 2 response, among patients with allergic 
asthma53, 54. A number of studies have shown elevated levels of periostin in polyp 
tissue from patients with CRSwNP compared to patients with CRSsNP, patients 
with allergic rhinitis and controls55, 56 and an upregulation of the periostin gene 
in nasal polyp tissue57. Elevated levels of periostin in nasal polyp tissue in CRS 
is associated with disease severity measured by elevated Lund-Mackay scores 
on computed tomography (CT) scans58, 59. Serum and nasal periostin levels are 
decreased after treatment with oral glucocorticoid steroids (GCS), doxycycline, 
omalizumab and mepolizumab in CRSwNP patients60.
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2.5 Mucosal remodeling
In CRS, the sino-nasal mucosa is altered with changes in tissue structure and 
extracellular matrix protein deposition. Different patterns are seen in CRSwNP 
compared to CRSsNP. CRSsNP is characterized by fibrosis and goblet cell hyper-
plasia61 whilst CRSwNP is characterized by formation of pseudocysts, inflammatory 
cell infiltrates, albumin and fibrin deposition and stromal tissue oedema within 
the polyps62. In CRSwNP, thickening of the basal membrane is related to disease 
severity and duration and is linked to underlying asthma and aspirin exacerbated 
respiratory disease (AERD) comorbidity63. The remodelling seen in CRSwNP is 
much like the one seen in asthma62, despite the different embryonic origin of the 
sino-nasal and tracheal epithelium (ectoderm vs endoderm).  In CRSwNP, the 
integrity of the epithelial barrier is compromised with a decreased expression of 
tight junctions and with an increased general permeability as result64. The under-
lying mechanism of remodelling is not fully understood, previously the chronic 
inflammation was thought to start the event but the notion that remodelling exists 
in early stages of the disease suggests that the remodelling occurs in parallel rather 
than as a result of inflammation65. 
2.6 Diagnostic tools
2.6.1 Clinical investigation
A variety of clinical diagnostic tools are available to diagnose CRS. However, the 
diagnosis is often made at primary health care centres based on symptoms alone. 
Nasal endoscopy helps phenotyping CRS into CRSwNP or CRSsNP, where polyps 
or swelling and/or mucopurulent discharge is easily identified. Nasal endoscopy 
is a standard examination that can be done with or without decongestant and local 
anaesthesia. CT-scans show the extent of the disease and possible anatomical 
details, important when planning surgery1. Information on comorbidities such as 
asthma and AERD is important in order to predict response to ordinary treatment 
and the likely progress of disease66, but clinical investigation and medical history 
cannot alone identify different endotypes. 
2.6.2 Biomarkers
Eosinophils in nasal polyp tissue is commonly used as an indicator of eosinophilic 
disease in nasal polyp patients. However, there is little or no consensus on cut-off val-
ues to determine tissue eosinophilia67. Blood eosinophilic count (EBC) is commonly 
used as a surrogate marker, the correlation between eosinophils in nasal polyp tissue 
and EBC is however not strong and changes after surgery68 or pharmacotherapy69. 
Several different potential biomarkers have gained interest as markers of CRS in 




Current treatment options of CRS consist of saline irrigation and intra nasal GCS 
as first line therapy, short courses of per oral GCS and antibiotics as adjuvant 
therapy and Functional Endoscopic Sinus Surgery (FESS) in case of failure 70. 
Patients who choose to undergo surgery have lower QoL scores than patients who 
stay on the first line therapy71. A group of patients with CRSwNP, especially those 
with asthma, AERD and patients with SE-IgE in nasal polyp tissue, experience no 
or little effect of traditional pharmacologic treatment or experience rapid recur-
rence of the disease after surgery72. All through the years, different types of surgi-
cal approaches of CRS have been used ranging from the least extensive “polyp 
extraction” to the most extensive “nasalization” procedures.73-75. Despite different 
surgical techniques the relapse rates in CRSwNP after surgery is reported to be 
40-90% depending on follow-up time9, 76, 77. Randomised controlled surgical stud-
ies give rise to several difficulties, and therefore large reliable studies are missing. 
2.7.2 Novel treatments
Given the pathophysiological similarities between CRSwNP and asthma, the new 
medications in asthma, mainly mAbs targeting type 2 inflammatory responses, 
have rendered a lot of interest also in the CRSwNP field. The results for some of 
the treatments are promising. 
2.7.2.1 IL-4/IL-13 – Dupilumab (Dupixent®)
Targeting the IL-4 or IL-13 pathways separately, have not proven successful in 
asthma32, 53. However, since IL-4 and IL-13 have shared signalling pathways the 
possibility to block both these cytokines has rendered some attention. Dupilumab 
is a fully humanized mAb targeting the IL4Ra subunit and inhibits both IL-4 and 
IL-13 signalling pathways 78. Dupilumab has proven to be effective in the treat-
ment of asthma, improving lung function and reducing the number of exacerba-
tions in patients with uncontrolled persistent asthma79. In patients with atopic 
dermatitis dupilumab treatment reduces the Eczema Area and Severity Index 80. 
In CRSwNP patients, dupilumab reduces the nasal polyp score, it also improves 
smell, CT-scores, and QoL 81, 82. Dupilumab is the first mAb approved for the treat-
ment of CRSwNP in USA and Europe. 
2.7.2.2 IgE – Omalizumab (Xolair®)
Omalizumab is a fully humanized mAb that binds to free circulating IgE via the Ce3 
domain and thereby reducing free IgE by 84-99%. By blocking the binding of IgE 
to the high-affinity IgE receptor on mast cells and basophils, the allergen-induced 
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degranulation is averted and the effect of the release of inflammatory mediators 
and cytokines is inhibited. Omalizumab treatment also leads to a down-regulation 
of IgE receptors on dendritic cells, mast cells and basophils 83-85. Omalizumab is 
approved for treatment of persistent moderate-to-severe asthma. Patients with 
CRSwNP treated with omalizumab show a significant reduction in nasal polyp 
score in the same magnitude as three weeks’ treatment with per oral GCS, but 
the effect of omalizumab lasted longer and showed less side effects compared to 
systemic GCS therapy86. Omalizumab is not yet approved for the treatment of 
CRSwNP but is used as off-label treatment in many clinics. Two phase 3 studies 
regarding omalizumabs effect on CRSwNP have been completed, reports indicate 
that they meet primary and key secondary endpoints; but results have not yet been 
published (Clinical trial number NCT03280537 and NCT03280550).
2.7.2.3 IL-5 – Mepolizumab (Nucala®)
Mepolizumab is a fully humanized IgG1 mAb that binds with high affinity to 
free IL-5, preventing its binding to the IL-5 Receptor a expressed on eosinophils 
and its progenitors 87. Several studies have shown reduction of sputum and blood 
eosinophils, a significant reduction of asthma exacerbations, improved QoL scores 
and reduced need of oral corticosteroids 87-91. Mepolizumab is now approved for 
treatment of severe refractory eosinophilic asthma with EBC>300cells/microL. 
In 2011, a randomized placebo controlled trial was published where patients with 
severe nasal polyposis refractory to corticosteroid therapy received two mepoli-
zumab or placebo injections 28 days apart. 60% of the treated patients demonstrated 
a significantly improved nasal polyp score and CT score. This change, along with 
improved smell was maintained for up to 36 weeks’ post treatment, indicating a 
long-term effect of mepolizumab 92.One phase 3 study regarding mepolizumabs 
effect in CRSwNP has been completed (Clinical trial number NCT03085797) but 
results have so far not been published. 
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3 MATERIALS AND METHODS
This section contains a brief description of materials and methods used in the 
 different studies. More information can be found in the individual papers I-V.
3.1 Human subjects
Paper I – Patients from Belgium, Sweden, Netherlands, Finland and Germany par-
ticipating in the GA2LEN cohort (Global Asthma and Allergy European Network) 
were included. Based on nasal endoscopy and medical history, they were divided 
into CRSwNP (n=136) and CRSsNP (n=116). In addition, 104 controls were 
recruited. Sino-nasal tissue and blood samples were collected during surgery.
Paper II – The Ghent database: Between May 2007 and June 2018, patients who under-
went surgery in the nose and/or sinuses at the Department of Otorhinolaryngology, 
Ghent University Hospital, Belgium were asked to be included in a research data-
base. Prior to surgery, clinical characteristics were recorded, and at the time of 
surgery tissue samples were collected. The total number of patients in the database 
was 1459. CRS patients with complete information on history of asthma, inhalant 
allergy and AERD comorbidity as well as results on tissue samples for IgE, IL-5, 
ECP and SE-IgE were selected from the database. In a subgroup of CRSwNP 
patients (n=140), EBC was also available. AERD was defined as patient reported 
respiratory reaction to non-steroidal anti-inflammatory drugs. Asthma was defined 
as patient reported use of asthma medication. Allergy was defined as patient 
reported symptoms of inhalant allergy.
Paper III – A randomized placebo controlled phase II study where 60 patients 
with CRSwNP were included81. The study was conducted at 13 sites in US and 
Europe (Belgium, Sweden, Spain) between August 2013 and August 2014. Eligible 
patients were aged 18-65 years and had symptoms of CRS despite treatment with 
intra nasal GCS spray and a nasal polyp score of at least 5 (at least 2 per nostril). 
Patients received dupilumab (N=30) or placebo (N=30) subcutaneously once a 
week during 16 weeks. Nasal secretions were collected at inclusion and every 
4 weeks, and in a subgroup of patients (n=12) nasal polyp tissue was obtained.
Paper IV – CRSwNP patients (n=84) who underwent sinus surgery for nasal polyps 
between January 2015 – August 2016 were reviewed. Patients lost to follow-up 
within seven months after surgery were excluded. In total 50 patients were included 
in this study. Patients who underwent a standard FESS with the minimal invasive 
mucosa sparing technique were considered controls and called non-reboot (n=20), 
while patients who underwent the reboot technique were considered cases (n=30) 
and subdivided into two groups; full reboot (with Draf III) (n=12) and partial 
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reboot (without Draf III) (n=18). SNOT-22 were sent out to all study subjects by 
mail in January 2018 and in March 2018. All patients were given the same post-
operative care and follow-up. 
Paper V – Patients aged 18 years or older with symptomatic bilateral severe 
CRSwNP scheduled for sinus surgery at the Department of Otorhinolaryngology, 
Ghent University Hospital, Belgium were included. Nasal polyps and affected 
mucosa from the different sinuses, and biopsies from the middle turbinate were 
collected, in total 76 samples from 11 patients. Inferior turbinates from healthy 
patients undergoing rhino-septoplasty was used as controls. 21 patients who 
underwent re-boot surgery were followed-up during 12 months post-operatively. 
At surgery, nasal polyp biopsies, serum and nasal secretions were collected and at 
12 months’ follow-up nasal secretions and serum were collected. Nasal secretions 
and serum samples from healthy patients (n=13) participating in the GA2LEN 
cohort were used as controls. 
Nasal polyp score (paper III, IV, V) – 4 points on each side, maximum 8 points. 
Polyp score Polyp size
0 No polyps
1 Small polyps in the middle meatus not reaching below the  middle turbinate
2 Polyps reaching below the lower border of the  middle turbinate
3 Large polyps reaching the lower border of the inferior turbinate or  polyps medial to the middle turbinate
4 Large polyps causing complete obstruction of the  inferior nasal cavity
Polyp recurrence (paper IV, V) – nasal polyp score of at least one on either side. 
Exclusion criteria  (paper I-II, IV-V) –  patients with other disorders, such as cystic fibrosis, 
primary ciliary dyskinesia or Eosinophil granulomatosis with polyangiitis (EGPA) and 
patients participating in other studies of monoclonal antibody treatment were excluded. 
Reboot technique (paper IV, V) – endoscopic sinus surgery includ-
ing clearing all polyps and sinus mucosa down to the periosteum from all 
sinuses. With or without Draf III, depending on involvement of the fron-
tal sinus. The inferior, and when possible, the middle turbinate is preserved. 
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Draf III (paper IV-V) – a surgical technique creating a wide, joint, opening to the 
frontal sinuses by resection of the frontal sinus floor and superior nasal septum93. 
Preoperative treatment (paper I, II, IV, V) – all patients were asked to stop 
intra nasal and per oral GCS treatment two and four weeks prior to surgery. 
Postoperative treatment (paper IV, V) – Nasal douching, doxycycline 100mg per 
day for three months and topical GCS drops containing fluticasone propionate. 
Location (paper II, IV, V) – all patients underwent surgery at the Department 
of Otorhinolaryngology at Ghent University Hospital in Belgium. 
Ethical approval (paper I-V) – All studies were approved from ethical committees 
at respective study site and all patients signed informed consent prior to inclusion. 
SNOT-22 (paper IV) – disease specific symptom score. 22 questions scored 0-5, 
maximal score 110. Higher scores represent worse symptoms94, 95.
3.2 Sino-nasal tissue (paper I-V)
Sino-nasal tissue was obtained during scheduled surgery (paper I, II, IV, V). In paper 
III nasal polyp biopsies were obtained at the open patient clinic after topical applica-
tion of local anesthesia (nafazoline 0.17 mg/ml and lidocainhydrochloride 34 mg/ml) 
for 15 minutes carefully making sure that the polyp score was not altered. All tissue 
was snap frozen in liquid nitrogen and stored at –80º C until analysis. Snap-frozen tis-
sue samples were homogenized and disrupted at 50 Hz for 2 minutes with the Tissue 
Lyser LT (Qiagen Benelux, Antwerp, Belgium) and 1 ml 0.9% NaCl with Complete, an 
EDTA-free protease inhibitor (Roche Diagnostics Belgium, Vilvoorde, Belgium), was 
added per 0.1 g of tissue27, 96. In paper IV type 2 inflammation in tissue was defined as 
IL-5 > 12.98pg/g and SE-IgE positivity in tissue was defined as SE-IgE > 3.85kUA/g11. 
3.3 Nasal secretions (paper III, V)
Nasal secretions were obtained by inserting Post-operative sinus packings (3.5 cm 
IVALON®, Fabco®, New London, CT, USA) into the nasal cavities and left for 5 
minutes. 3 mL of saline (0.9% NaCl) was added to each of the tubes and they were 
then incubated for 2 hours. The tubes were centrifuged at 1500xG for 15 minutes 
at 4º C97. In paper III the analyzed nasal secretions were reported without further 
normalization, in paper V the results were reported after normalization to weight.
3.4 Blood samples (paper I, II, V)
In paper II, blood samples were collected at the open patient clinic and analysed for 
total eosinophilic count according to regular guidelines at the laboratory at Ghent 
University Hospital. In paper I and IV, blood samples were collected routinely 
prior to surgery and in paper V also at twelve months’ follow-up. The serum was 
stored in -25º C until analysis.
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3.5 Antibody assays
3.5.1 Periostin (Paper I)
Serum periostin was measured using the clinical trial version of the Elecsys® 
Periostin assay on the e 601 module of the cobas 6000 system98. The Elecsys® 
Periostin assay is a fully automated assay similar to an ELISA. A sandwich complex 
is formed between periostin, a biotinylated antibody and a ruthenylated antibody, 
and is captured on the surface of added streptavidin-coated micro particles. The 
amount of captured complex and therefore the periostin level in the sample is 
measured using electrochemiluminescence technology. The two antibodies that are 
used target different epitopes of periostin allowing a more specific measurement. 
3.5.2 Enzyme-linked immunosorbent assay – ELISA (paper III)
ELISA is a method for detection and quantification of an antibody or antigen in a 
sample. A sandwich-ELISA (Quantikine ELISA Kit®, R&D Systems, Minneapolis, 
MN, USA) was used for quantification of eotaxin -3 in saline eluates from nasal 
swabs. The ELISA used was based on a microplate pre-coated with antibodies 
against the antigen of interest. When adding a sample to the microplate, potential 
antigens in the sample bind to the antibodies. After washing away unbound sub-
stances, an enzyme-linked polyclonal antibody specific for the antigen of interest 
is added and after adding a substrate solution, a color develops which is propor-
tional to the amount of bound antigen. 
3.5.3 ImmunoCAP fluorescent enzyme immunoassay (paper I-V)
Different types of ImmunoCAP techniques were used to assess IgE, ECP and a 
mixture of SE-IgE (staphylococcal enterotoxins A (SEA) and C (SEC) and toxic 
shock syndrome toxin 1 (TSST-1)) in serum, nasal secretion and sino-nasal tissue 
homogenates in paper I-V. ImmunoCAP is a method used for the quantification 
of an antibody similar to an ordinary sandwich ELISA but where the reaction 
takes place in a solid phase. An antigen is covalently coupled to the solid phase 
and binds to the antibody of interest. After washing, enzyme labeled antibodies 
against the marker are added to form a complex. Following incubation, the unbound 
enzyme-anti-marker is washed away and the bound complex is then incubated 
with a developing agent. After stopping the reaction, the fluorescence of the elu-
ate is measured. The fluorescence is directly proportional to the concentration of 
the marker in the sample. The higher the response, the more marker is present in 
the sample. The UniCAP system is a predecessor of ImmunoCAP. In paper I-V 
the UniCAP system (Phadia, Uppsala, Sweden/ Thermo Fisher Scientific, Phadia, 
Grootbijgaarden, Belgium) was used. In paper II the ImmunoCAP (Phadia AB, 
Uppsala, Sweden) was used for assessing biomarkers in nasal secretions. 
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3.5.4 Luminex (paper I-V)
Luminex immunoassay was used for measuring multiple cytokines99, for example 
interleukins and chemokines, in serum samples, nasal secretion and sino-nasal 
tissue homogenates. Commercially available kits (Luminex Performance Assay/
Screening Human assay) were used and measured on a Bio-Plex 200 Platform 
(Bio-Rad Laboratories Temse, Belgium). Luminex is a technology in which  several 
proteins or peptides in one sample can be quantified. The method is similar to 
sandwich-ELISA, with the exception that magnetic beads dyed with fluorescent 
dyes are covalently coupled to the antibodies directed against the antigen of interest. 
Each bead thus has a distinct colour code permitting discrimination of individual 
antigens. Generally, Luminex has lower detection limits than an ELISA and is 
more time efficient but can be more expensive. Another advantage is that only a 
small sample volume is needed. 
3.6 Statistical methods (paper I-V)
Graph Pad Prism version 7 and 8 for Mac OS X (GraphPad Software, Inc., La 
Jolla, CA) was used for all statistics, except in the prediction model in paper 
II and for calculations of nasal secretions in paper III where STATA Statistical 
Software, version 13.1 (Stata Corp, College Station, Texas) was used and in paper 
IV where Statistical Package for Social Sciences, version 25.0 (SPSS, Chicago, IL) 
was used for the Kaplan-Maier curves. Non-parametric tests were used since the 
data were not normally distributed. A p-value < 0.05 was considered significant. 
Mann-Whitney (paper I, II, IV) was used to compare median levels between two 
groups. The Kruskal-Wallis test with Dunn’s multiple comparison (paper I, IV, V) 
was used to assess differences in median levels between more than two groups. The 
Wilcoxon test (paper III, IV) was used for paired analysis. Spearmen correlation 
test (paper I, II) was used to assess correlations, and the results were interpreted 
as suggested by Hinkle et al100 (R=0.9-1 very high positive, R=0.7-0.9 high posi-
tive, R=0.5-0.7 moderate positive, R=0.3-0.5 low positive, R=0.0-0.3 negligible). 
Chi2-test (paper II) or Fisher’s exact test (paper I-V) was used to compare propor-
tions101. ROC-curves (paper I) were used to determine best cut-off between serum 
periostin, IgE and SE-IgE and IL-5 and SE-IgE positivity in tissue. For biomarkers 
in nasal secretions in paper III, the areas under the concentration versus time curves 
from time of first treatment to week 16 (AUC0-16) were estimated by trapezoidal 
analysis. The comparison of treatment effects from the mixed-effect model with 
repeated measures analyses were based on the LS mean change (with 95% con-
fidence intervals and P values) from baseline to Week 16. 
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4 RESULTS AND COMMENTS
4.1 Inflammation in severe CRSwNP (paper V)  
Our aim was to understand whether inflammation in severe type 2 CRSwNP 
was limited to the polyps or if the non-polypoid sinus mucosa also contributed. 
11 patients scheduled for reboot surgery at Ghent University Hospital, Belgium, 
were included. During surgery, polyps and non-polypoid mucosa from the differ-
ent sinuses, polyps from the nose and middle turbinate tissue were obtained, in 
total 76 samples. 16 inferior turbinates from healthy patients were used as con-
trols. Polyps and non-polypoid mucosa from all the sinuses and polyps in the nose 
expressed elevated levels of IgE, ECP and IL-5 compared to control tissue. The 
middle turbinate expressed elevated levels of IgE, ECP but not IL-5. (Figure 3)
Figure 3: Concentrations of IgE, ECP and IL-5 in tissues from the different locations. The 
boxes indicate the median and IQR, error bars min;max; Kruskal-Wallis test with Dunn’s 
multiple comparison; *** p≤0.001, ** p≤0.01, * p<0.05, ns; not significant. ES; ethmoid 
sinus, MS; maxillary sinus, SS; sphenoid sinus, FS; frontal sinus, NP; nasal polyp, MT; 
middle turbinate. 
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Polyps and non-polypoid mucosa expressed elevated levels of IgE, ECP and IL-5 
compared to controls, no difference was seen between polyps and non-polypoid 
mucosa. (Figure 4) 
Figure 4: Concentrations of IgE, ECP and IL-5 in polyps (P), non-polypoid mucosa (M) 
and control tissue (C). The boxes indicate the median and IQR; Kruskal-Wallis test with 
Dunn’s multiple comparison; *** p≤0.001, ** p≤0.01, * p<0.05
4.1.1 Comments 
In severe type 2 CRSwNP, all sinuses expressed elevated levels of type 2 inflam-
matory markers compared to controls. The inflammation was not limited to the 
actual polyps but was equally present in non-polypoid sinus mucosa.
4.2 Type 2-shift in CRS (paper II)
There are wide geographical and phenotypical differences with the regard to 
inflammatory background in CRS24. In Asia, a shift from type 1 towards type 2 
inflammation in CRSwNP has been described102. We aimed to investigate whether 
this shift can be seen in CRS in Western Europe as well. 
4.2.1 CRSwNP
CRSwNP patients who underwent surgery at University Hospital in Ghent 
during two different time periods (2007-2010 and 2016-2018) were com-
pared. The two cohorts were equal regarding gender, age and comorbidities. 
The proportion of patients who had previous sinus surgery were not different. 
In the CRSwNP patients (n=102 and n=90), an increase in tissue levels of IgE, 
ECP and IL-5 was seen in the later cohort compared to the earlier. When stratified 
for comorbidities, the increase could only be seen in non-asthmatic, non-allergic 
patients (figure 5), among these, a higher proportion of patients also had IL-5 posi-
tive polyps (63.4% vs 86.7% p=0.033). There was no difference in EBC between 
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the two cohorts (median (IQR) 2007-2010 293.5(162.0;574.8) 2016-2018 420.0 
(235.0;747.5 p=0.147)). Also, in this group, there were no differences in comor-
bidities or proportions of patients with a history of previous surgery.
Figure 5: IgE, ECP and IL-5 in patients without asthma/allergy. Levels presented as median 
and IQR. ** p≤0.01, Mann-Whitney.
4.2.2 CRSsNP
CRSsNP patients who underwent sinus surgery at the University Hospital in Ghent 
during two different time periods (2007-2010 and 2015-2018) were compared. The 
two groups were similar in regard to comorbidities. In CRSsNP patients (n=39 
and n=26) ECP and IL-5 were elevated in the later cohort compared to the earlier 
(figure 6). This increase was, as for the CRSwNP patients, only seen in the non-
asthmatic group (n=31 vs n=18). In the proportion of patients who were positive 
for IL-5 or SE-IgE in nasal polyp tissue, no differences were seen. 
Figure 6: Levels of IgE, ECP and IL-5 in CRSsNP tissue. Levels presented as median and 
IQR. * p<0.05. Mann-Whitney. 
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4.2.3 Comments
Our data suggests an actual shift of endotype in CRSwNP patients over time, with 
elevated levels of IgE, ECP and IL-5, and an increase of the proportion of IL-5 
positive patients, much like the shift seen in parts of Asia102-104. Interestingly, the 
shift was only seen in non-asthmatic patients. This shift, towards a type 2 endotype, 
also seemed to be happening in CRSsNP patients, although not as pronounced, 
also here only observed in non-asthmatic patients. However, due to a small cohort 
of asthmatic patients these results must be interpreted with some caution. The 
results could be due to a selection bias. Using asthma and AERD comorbidities 
and the proportion of patients who had undergone previous surgery as a marker of 
disease severity, no differences were seen between the cohorts, and the shift was 
only present in non-asthmatic patients, i.e. patients with a mild form of disease. 
4.3 Endotypes and phenotypes; effect on type 2 
 inflammatory markers (paper II)
4.3.1 IL-5 positive and negative CRS
438 patients with CRS (CRSwNP n=323, CRSsNP n=115) participating in a 
research database in Ghent, Belgium, were included. Patients were stratified on 
phenotype i.e. presence or absence of polyps. IL-5 positive patients, regardless of 
phenotype, expressed elevated levels of IgE and ECP compared to IL-5 negative 
patients. In the IL-5 positive group there was a significant difference in comor-
bidities (asthma, 45.6% vs 30.0% p=0.031, AERD 19.9% vs 5.0% p=0.004) and 
in SE-IgE positivity in polyps (45.2% vs 26.7% p=0.009) between CRSwNP and 
CRSsNP, allergy did not differ between the groups. This difference was not seen 
in the IL-5 negative group (figure 7). 
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Figure 7: Levels of IgE and ECP in IL-5 positive (IL-5+) and IL-5 negative (IL-5-) in 
CRSwNP and CRSsNP patients and levels of IL-5 in IL-5 positive CRSwNP and CRSsNP 
patients. Dots are individual values. Circles in grey indicate individual values above the 
maximal range of the y-axis. *** p≤0.001. Numbers and proportion of patients with asthma, 
allergy, AERD and SE-IgE positivity in polyps in the different groups, significant numbers 
indicated with *. Kruskal-Wallis test with Dunn’s multiple comparison, Mann-Whitney, 
and Fisher’s exact test. 
4.3.2 Comorbidities impact on type 2 markers in CRSwNP 
323 CRSwNP patients were stratified based on asthma and/or AERD comorbidity. 
CRSwNP patients with asthma and/or AERD expressed elevated levels of IgE, ECP 
and IL-5 compared to CRSwNP patients without asthma and/or AERD. AERD 
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comorbidity did not enhance levels of IgE or IL-5 compared to asthma only, ECP 
was elevated in AERD compared to asthma (figure 8).
Figure 8: IgE, ECP and IL-5 in patients without asthma or AERD, with asthma only, with 
asthma and AERD. Mutually exclusive groups. Levels presented as median and IQR. 
*** p≤0.001, ** p≤0.01. Kruskal-Wallis test with Dunn’s multiple comparison. Number 
and proportion of IL-5 and SE-IgE positivity in polyps.  
4.3.3 Comments
Within the CRS group, two different types could be identified, IL-5 positive and 
IL-5 negative patients based on inflammatory levels in sino-nasal polyps. IL-5 
negative patients seemed to be more coherent, in terms of inflammatory patterns 
and comorbidities, regardless of endotype, compared to IL-5 positive patients 
where the CRSwNP patients had elevated levels of inflammatory markers and 
type 2 related comorbidities. Levels of type 2 inflammatory parameters were not 
directly linked to polyp formation. CRSwNP patients with asthma and/or AERD 
expressed elevated levels of IgE, ECP and IL-5. AERD did not seem to enhance 
the levels of IgE and IL-5, suggesting that asthma itself can cause maximal type 2 
inflammation. However, ECP is elevated in AERD, as seen in previous studies105. 
4.4 Identifying type 2 inflammation in CRSwNP; clinical 
markers and biomarkers (paper I and II)
It has been difficult to identify biomarkers and clinical signs to properly endotype 
CRS, which is crucial in order to implement a personalized approach to CRS treat-
ment. We therefore explored a combination of novel and traditional biomarkers 
and comorbidities to identify type 2 inflammation in sino-nasal polyps. 
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4.4.1 Serum periostin, IgE and SE-IgE (paper I)
377 patients participating in the GA2LEN cohort were included. Based on history 
and nasal endoscopy they were divided into CRSwNP (n=144), CRSsNP (n=123) 
and controls (n=110). Serum and tissue samples from these patients were analysed 
for type 2 inflammatory markers. Serum levels of periostin were elevated in patients 
with CRSwNP compared to CRSsNP and controls (figure: 9).
Figure 9: Serum periostin in CRSwNP, CRSsNP and controls. Median and IQR. Kruskal-
Wallis with Dunns’ multiple comparison. *** p≤0.001. 
ROC analyses were performed to see whether serum markers could predict presence 
of IL-5 and/or SE-IgE in polyp tissue in CRSwNP patients. 108 CRSwNP patients 
had a full dataset for serum markers, tissue IL-5 and tissue SE-IgE. 85.2% of these 
patients were IL-5 positive in nasal polyp tissue. Serum periostin > 48.5ng/ml 
predicted for IL-5 positivity with a sensitivity of 93.5% and a specificity of 63.5% 
(p<0.0001). 20.4% of the patients were SE-IgE positive in nasal polyp tissue, all 
of them had serum periost in 48.5ng/ml. Among these patients (n=92), serum IgE 
> 96kUA/l and serum SE-IgE > 28kUA/l predicted for SE-IgE positivity with a 
sensitivity of 77.3% and a specificity of 87.1% (p<0.0001) (table 1). 
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N=108 Cut-off level  
(proportion positive)
AUC Sensitivity Specificity p-value
Tissue IL-5 positive (n=92)
serum Periostin 48.5 ng/ml (86/92) 0.78 93.5% 62.5% <0.0001
N=92
Tissue SE-IgE positive 
(n=22)
serum IgE 96 kUA/l (19/22) 0.8 86.4% 67.7% <0.0001
serum SE-IgE 0.28 kUA/l (17/22) 0.8 77.3% 75.7% <0.0001
Serum IgE, SE-IgE (17/22) 77.3% 87.1% <0.0001
Table 1: Cut-off concentrations, proportions of positive patients, area under the curve and 
sensitivity, specificity and p values for predicting IL-5 and SE-IgE in tissue using serum 
periostin, IgE and SE-IgE. P-value calculated with Fisher’s exact test.
4.4.2 Blood eosinophil count and comorbidities (paper II)
140 patients with CRSwNP who underwent sinus surgery at Ghent University 
Hospital was included. Comorbidities, EBC and type 2 inflammatory markers 
in tissue were assessed. EBC was elevated in patients with asthma and/or AERD 
compared to CRSwNP patients without asthma/AERD (figure 10). 
Figure 10: Blood eosinophilic count in patients without asthma/AERD, with asthma 
only and with asthma and/or AERD. Levels presented as median and IQR. *** p<0.001, 
** p≤0.01, * p<0.05. Kruskal-Wallis test with Dunn’s multiple comparison.
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There were rather weak positive correlations between EBC and tissue inflamma-
tory markers, tissue IgE (R=0.415, p<0.001), SE-IgE (R=0.214, p=0.011) ECP 
(R=0.410, p<0.001) and IL-5 (R=0.489, p<0.001). A prediction model based on 
chi2-test (or Fisher’s exact test when appropriate) was developed to investigate if 
any of the clinical markers, asthma, AERD and allergy comorbidity and EBC > 300 
cells/microL could be used to identify patients with or without IL-5 positivity and 
SE-IgE positivity in nasal polyp tissue. In the total group, the likelihood of IL-5 
positivity was 84.3%. Among patients with asthma or AERD, 94.2% were IL-5 
positive (p<0.001). In patients without asthma/AERD the likelihood was 68.5%, 
but with an EBC>300cells/microL the likelihood increased to 95.2% (p<0.001). 
Regarding SE-IgE, 40.7% of the patients were positive. The likelihood of SE-IgE 
in tissue among patients with asthma/AERD was 48.8% (p=0.014). The group with 
asthma/AERD and EBC> 300 cells/microL had a higher proportion of SE-IgE 
positivity in nasal polyp tissue compared to the group without asthma/AERD and 
EBC<300cells/microL (p=0.002, 57.9% vs 21.9%). (Figure 11). 
No
CRSwNP n=140
IL-5 posive 84.3% 
Asthma/AERD/Allergy Yes
IL-5 + 94.2%p<0.001IL-5 + 68.5%
NoEOS > 300 Yes
























Figure 11: A prediction model for tissue IL-5 positivity and tissue SE-IgE positivity based 
on clinical markers, asthma and/or AERD and/or allergy comorbidity and elevated blood 
eosinophils (EBC > 300 cells/microL). P-values obtained by Chi2–test or Fisher’s exact test. 
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4.4.3 Comments
Serum periostin was elevated in CRSwNP patients compared to CRSsNP patients 
and controls, and could, together with serum IgE and SE-IgE, be used with reason-
able sensitivity and specificity to identify type 2 CRSwNP. Tissue eosinophilia 
is commonly used to diagnose eosinophilic CRSwNP, however there is little or 
no consensus on cut-off levels of meaningful eosinophilia67. EBC has been sug-
gested as a surrogate marker, in our results however, there was a weak or no cor-
relation between EBC and type 2 inflammatory markers in polyp tissue. EBC 
can, together with questions about comorbidities relevant for type 2 disease, help 
identify CRSwNP patients with tissue IL-5 expression. 
4.5 Novel treatments (paper III-V)
CRSwNP patients experienced relapse after surgery in 40-90% of cases,  depending 
on follow-up time9, 76, 77. Therefore, new treatment strategies for this patient group 
are required. 
4.5.1 Dupilumab – effect on local inflammatory markers (paper 
III)
In recent years, studies on mAbs, targeting different aspects of the type 2 inflam-
matory response have been carried out with promising results in CRSwNP patients 
for some therapies86, 92 with reduction of nasal polyp score and an improvement 
of symptom scores. 
We performed a post-hoc analysis of a randomized, double-blind, placebo-controlled 
phase II study regarding treatment effects of dupilumab81 in CRSwNP patients. 
60 patients with CRSwNP were included in this study. Patients received either a 600mg 
loading dose of dupilumab followed by 16 weeks of 300 mg dupilumab or matched 
placebo. All patients were on mometasone furoate nasal spray (100mg/nostril twice 
daily) 4 weeks prior to inclusion and continued with this throughout the study. Nasal 
secretions were obtained at inclusion and every 4 weeks of the study, nasal biopsies 
were obtained in a subgroup of patients (n=12) at inclusion and at the end of treatment. 
There was a decrease in total IgE and eotaxin-3 in nasal secretions in the dupilumab 
group compared to placebo (LS mean AUC0-16 [±SE]; total IgE vs placebo (−7.90 
[1.9] vs −1.86 [2.1] IU/ml; p=0.022): eotaxin-3 −30.06 [5.9] vs −0.86 [6.6] pg/ml; 
p<0.001). In nasal polyp tissue a decrease of total IgE (p=0.023) ECP (p=0.008), 
eotaxin-2 (p=0.008), eotaxin-3 (p=0.031), IL-13 (p=0.031) and pulmonary and 
activation-regulatory cytokine (PARC) (p=0.016) was observed from inclusion to 
end of treatment in the dupilumab group, no changes were found in the placebo 
group (table 2). 
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Change from inclusion Dupilumab p-value Placebo p-value
IgE U/g median (IQR) -139.2 (-384.7;-36.0) 0.023* -97.6 (312.3;350.9) >0.999
ECP ng/g median (IQR) -7310.0 (-9591.0;-5129.0) 0.008* -665.0 (-2855;10393.0) >0.999
Eotaxin 2 pg/g median 
(IQR) -4117.0 (-23163.0;-1271.0) 0.008* 833.1 (-5938.0;27540.0) 0.875
Eotaxin 3 pg/g median 
(IQR) -394.6 (-1892.0;-87.7) 0.031* -206.0 (-480.7;1583.0) 0.875
IL-13 pg/g median 
(IQR) -171.7 (-874.9;27.4) 0.031* -888.1 (-1928.0;-104.2) 0.250
PARC pg/g median 
(IQR) -320074.0 (-893531.0;-85552.0) 0.016* 179289 (1041;1012327) 0.250
Table 2: Changes in inflammatory markers in nasal polyp tissue from inclusion to end 
of treatment in the dupilumab and placebo group. Levels presented in median and IQR. 
Wilcoxon test. Significant numbers are indicated with*. 
4.5.2 Reboot surgery (paper IV and V)
Reboot surgery, is an extensive form of endoscopic sinus surgery, involving com-
plete removal of sinus mucosa down to the periosteum, with (full reboot) or without 
(partial reboot) a wide opening to the frontal sinuses (Draf III approach). In this 
way, the inflammatory burden is removed and the nasal mucosa can regenerate. 
Reboot surgery has been proposed to be more efficient in preventing relapse. 
4.5.3 Recurrence and symptom scores (paper IV)
82 patients who underwent endoscopic sinus surgery due to CRSwNP at the 
University Hospital in Ghent, Belgium, between 2015-2107 was reviewed. Patients 
who were lost to follow-up within 7 months’ post-surgery, and patients with con-
genital disorders such as cystic fibrosis were excluded. 50 patients remained and 
were included. 12 patients had undergone full reboot, i.e. including a Draf III 
procedure, 18 patients had a partial reboot, i.e. without a Draf III procedure and 
20 patients had a conventional mucosa sparing procedure (non-reboot). Baseline 
data, including asthma and AERD comorbidity, prior surgeries and nasal polyp 
score did not differ between the three groups. Type 2 inflammatory markers in 
nasal polyp tissue and serum did not differ between the groups. The reboot group 
had less relapses during follow-up (longest follow-up 30 months’ post-surgery) 
(relapse defined by a nasal polyp score of at least 1 on either side) (45% vs 13.3% 
p=0.02). A survival analysis showed superior results for the full reboot group, con-
cerning cases with relapse and time to recurrence, followed by the partial reboot 
and the non-reboot groups (table 3). 
28
Non-reboot Partial reboot Full reboot p-value
n 20 18 12
Recurrence n (%) 9 (45) 3 (16.7) 1 (8.3) 0.038*⊚





Recurrence n (%) 9 (45) 4 (13.3) 0.02*^
Table 3: Number and proportion of recurrence in non-reboot, partial reboot and full 
reboot; time to recurrence. Number and proportion in non-reboot and all reboot. ⊚Chi2-test, 
^Fischer’s exact test.
Despite a more extensive surgery, patients in the reboot group had significantly better 
SNOT-22 results 2 years after surgery compared to the non-reboot group (figure 12). 
Figure 12: SNOT-22 scores of reboot and non-reboot patients 2 years after surgery. * 
p<0.05. Mann-Whitney.
4.5.4 Reboot; effect on local and systemic inflammatory markers 
(paper V)
21 patients scheduled for reboot surgery at Ghent University Hospital, Belgium, 
were included. 52% had comorbid asthma, 10 % had comorbid AERD and 71% 
of the patients had had at least 1 prior surgery. Nasal secretions and serum were 
collected prior to surgery and at 12 months’ follow-up. Patients participating in 
the GA2LEN cohort was used as controls (n=13). Type 2 inflammatory markers 
(IgE, ECP and IL-5) in nasal secretions were elevated at inclusion in CRSwNP 
patients compared to controls. In CRSwNP patients a marked decrease was seen 
for IgE, ECP and IL-5 from inclusion to the end of the study but did not reach the 
levels of the controls (table 4). 
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Nasal 
secretions Inclusion 12 months Controls p-value^ p-value^ p-value¨












33.7 (2.4;309.2) 5.1 (2.1;62.6) not detectable - - 0.04*
Table 4: IgE, ECP and IL-5 in nasal secretions at inclusion and after 12 months compared 
to healthy controls. P-value obtained by Kruskal-Wallis test with Dunns multiple compari-
son (^) and Wilcoxon matched pair signed rank test (¨). Significant p-values are indicated 
with * B = baseline, C = control, 12m = 12 months.
Serum samples were available from 19 patients at both inclusion and at a 12 
months’ follow-up. No decrease in serum IgE, SE-IgE or ECP was seen. In 
the disease-specific SNOT-22 and the health related QoL questionnaire 
RAND-36, both the physical component scale (PCS) and the mental compo-
nent scale (MCS), were improved 12 months after surgery compared to base-
line (SNOT-22 p=0.003, RAND-36 PCS p=0.03, RAND-36 MCS p=0.046). 
Out of the 21 patients, three patients had a unilateral nasal polyp score of one twelve 
months after surgery and one patient had a bilateral polyp score of two.  These 
polyps could be removed in an open clinic setting under local anaesthesia. All 
patients had completely fine mucosa covering the sinus walls within 4-6 weeks and 
no patients suffered from major complications during surgery or postoperatively. 
4.5.5 Comments
The phase II study that paper III was based on showed a decrease in nasal polyp 
score and a rapid improvement of smell in the dupilumab group compared to pla-
cebo and a reduction of total IgE and eotaxin-3 in serum81. Our data suggest, that 
blocking the IL-4/IL-13 pathway affects mucosal IgE production and has an effect 
on eosinophilic activation, survival and migration. The reduction of ECP in nasal 
polyp tissue suggests a local reduction of activated eosinophils. The reduction 
of eosinophils could not be determined due to scant polyp material. Eotaxins are 
highly chemotactic to eosinophils and other inflammatory cells, and are known to 
prolong eosinophilic survival39, 42, mediate eosinophilic activation and direct tran-
sepithelial migration43, 44. A potential mechanism for reducing eosinophilic activa-
tion and infiltration in tissue, demonstrated by the reduction of eotaxins and ECP 
in nasal polyp mucosa and nasal secretions, may be a change in the chemotactic 
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gradient signaling eosinophilic migration from the blood stream into the tissue, 
which is in line with the rapid increase seen in blood eosinophils shortly after ini-
tiating dupilumab treatment81. The small number of patients available for polyp 
tissue analysis and the fact that all patients included were from Europe or USA 
are drawbacks of this study, our data is however coherent with a larger dupilumab 
phase III study recently published82. Reboot surgery reduces inflammatory mark-
ers in nasal secretion in the same magnitude as treatment with dupilumab, and the 
reduction is persistent for at least 12 months. Reboot surgery seems to be favorable 
in preventing relapse compared to conventional mucosa sparing surgery in terms 
of relapse rates and in time to recurrence implicating the need for more complete 
surgery. No patients participating in these reboot studies suffered from any seri-
ous complications intra- or postoperatively, such as orbital damage, cerebral fluid 
leakage or major infections.   
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5 DISCUSSION
CRS is a common disease with significant impact on patients’ quality of life, espe-
cially for patients with type 2 CRSwNP who often experience relapse of the disease 
after treatment. We have shown that the inflammation in CRSwNP is not limited 
to the polyps themselves, but is also present in the non-polypoid sinus mucosa. It 
is possible, that part of the reason for relapse after mucosal sparing surgery, is that 
this mucosa maintains an extensive inflammation which is not addressed during 
conventional surgery. Our results also show that all sinuses are equally inflamed, 
something that is supported by the findings in computed tomography studies after 
treatment with mAbs. These antibody-based drugs have previously been shown to 
reduce opacification in all sinuses (total Lund-Mackay scores) in severe CRSwNP 
patients106-109 supporting the notion of ongoing inflammation in all sinuses. 
In CRSwNP, there are geographical differences in the inflammatory background. 
A multicenter study has shown that European CRSwNP patients express predomi-
nantly type 2 inflammation whereas patients from Beijing show a mixed type 1/type 
2/type 17 inflammatory pattern, patients from Japan show higher individual type 2 
patterns compared to Beijing, but lower patterns than European patients23. A shift 
towards increased type 2 inflammation has been seen in Thailand102, Korea103 and 
China104 over recent years. We can now show that a similar shift towards increased 
type 2 inflammatory parameters and an actual shift of endotype, described as 
an increase in IL-5 positivity in tissue, is seen in Western Europe. Interestingly, 
this shift is only seen in non-asthmatic, non-allergic patients; asthmatic patients 
already show a high expression of IL-5, which obviously is not subject to further 
increase. If the shift is caused by an altered microbiome, environmental factors 
or something else is still to be investigated. We know that patients with type 2 
CRSwNP have a more severe form of CRSwNP and are more prone to relapse11. 
This observed increase in type 2 inflammation might mean that we will be fac-
ing more patients with severe and difficult to treat CRSwNP in the future, further 
illustrating the importance of being able to endotype these patients and to find 
novel treatment strategies. 
Here we describe two different entities of CRS based on levels of IL-5 in tis-
sues, IL-5 positive and IL-5 negative. IL-5 negative patients with and without 
nasal polyps are similar with no differences in levels of inflammatory markers 
or comorbidities, whereas IL-5 positive polyp and non-polyp patients express 
elevated levels of IgE and ECP compared to IL-5 negative patients. Within the 
IL-5 positive group, CRSwNP patients express elevated levels of IgE and ECP 
compared to CRSsNP patients and a higher proportion of CRSwNP patients have 
asthma and AERD comorbidity as well as presence of SE-IgE in polyp tissue. 
Interestingly, polyps appear in both groups, regardless of levels of type 2 markers, 
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as seen in non-type 2 CRSwNP23, 24. This suggests that the mechanism that drives 
polyp formation is independent from type or level of inflammation. It is possible 
that type 2 inflammation enhances the polyp disease once it has started, but the 
trigger might be something else. 
Patients with asthma have elevated levels of type 2 markers in nasal polyp tis-
sue and EBC. AERD comorbidity does not enhance this elevation, suggesting 
that asthma alone causes maximal inflammation. Nevertheless, a recent study 
has shown that patients with AERD had undergone more sinus surgeries than 
CRSwNP patients with asthma only (1.4vs 2.6)110 suggesting that patients with 
AERD have a more severe form of CRSwNP that is not reflected in polyp tissue 
type 2 inflammatory markers.
In order to implement personalized treatment for CRSwNP patients, they have to 
be properly endotyped. Serum periostin is elevated in CRSwNP patients compared 
to CRSsNP patients and controls and serum periostin, serum IgE and serum SE-IgE 
can be used to identify the most severe cases of CRSwNP, i.e. patients with IL-5 
and SE-IgE in nasal polyp tissue, with good sensitivity and moderate specificity. 
Except for serum IgE, these markers are not yet used in clinical practice. EBC is 
commonly used as a surrogate marker of tissue eosinophilia. In our data, there 
was a positive but poor correlation between EBC and inflammatory markers in 
tissue, when interpreting the results as suggested by Hinkle et al100 with only IL-5 
almost reaching up to a moderate positive correlation (R=0.489, p<0.001). Our 
prediction model reveals that elevated EBC (>300 cells/microL, the level used for 
treatment with mepolizumab in asthma) can, together with questions about asthma 
and AERD comorbidity, help to identify the least and the most severe cases of 
CRSwNP. After identification of type 2 inflammation in CRSwNP patients due 
to their comorbid asthma, an elevated EBC helps to identify tissue IL-5 positive 
CRSwNP patients without asthma/AERD/allergy, and can be very helpful in a 
clinical setting. However, EBC alone does not indicate the type or the severity of 
inflammation in the polyps. EBC is a difficult marker to use, since it can be affected 
by many other conditions, such as corticosteroid therapy, allergies, autoimmune 
diseases and parasite infections. A recent study showed an inverse relationship 
between EBC and oral GCS use69, hence consideration must be taken when the 
EBC test is executed. 
Recent studies have shown that monoclonal antibodies directed towards type 2 
immune responses to be effective in decreasing polyp size and improving symptom 
scores in CRSwNP patients81, 86, 92. Dupilumab, affecting the IL-4/IL-13 pathway, 
reduces local inflammatory type 2 parameters in tissue and in nasal secretions. The 
reduction in nasal secretions was 78.8% for IgE and 38.6% for ECP. These results 
point to a local effect on eosinophilic activation and migration. Dupilumab will 
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possibly shorten the lifetime of eosinophils although dupilumab does not directly 
reduce IL-5. Treatment studies of mepolizumab (anti-IL-5) have not shown a 
consistent decrease in nasal ECP, total IgE or IL-592.  IL-4 has, unlike IL-5, the 
ability to promote the maturation of naïve T0 cells into Th2 cells and to upregu-
late IgE receptors on the cell surface of mast cells, basophils, B-lymphocytes 
and mononuclear phagocytic cells and thus to upregulate IgE-mediated immune 
responses32. This can possibly explain the differences between the two medications 
on local inflammatory parameters. Dupilumab (Dupixent®) is, the only mAb so 
far, approved for CRSwNP, in USA and Europe, but is not yet in use in Sweden. 
Treatment with mAbs are expensive (yearly cost for one patient is between 120 000 
– 300 000 SEK) and possibly a life-long treatment is required to prevent relapse 
of the disease, and yet, one does not know which patients may respond. 
Surgical approaches in CRSwNP have differed, ranging from very extensive73 to 
minimal, with only opening the natural ostium and preserving the mucosa in order 
not to disturb the mucocilliary clearing74, 75. Despite different techniques, relapse 
in severe type 2 CRSwNP after surgery is common. Reboot surgery addresses, 
unlike the conventional mucosa sparing surgery, the non-polypoid inflamed tissue 
in all sinuses, hence removing inflammatory cells and other triggers, such as Staph. 
Aureus that, when left, can cause the inflammation to persist. This is probably part 
of the success in terms of relapse rates, where reboot is superior to mucosa sparing 
surgery. Despite extensive surgery, reboot patients report significantly improved 
SNOT-22 scores one year after surgery compared to patients undergoing mucosa 
sparing surgery. Reboot surgery positively affects local inflammation in the nose, 
measured as a decrease in levels of type 2 inflammation. This decrease is in the 
same range as reported after treatment with dupilumab111. The decrease in inflam-
matory parameters persists for at least 1 year after surgery, but does not decrease to 
the levels of healthy individuals. Even so, patients do not relapse in their disease 
at the same speed112 as after mucosa sparing surgery. A previous study has shown 
that inferior turbinates from severe CRSwNP patients contain elevated levels of 
type 2 inflammatory markers compared to healthy inferior turbinates113. Here, we 
show that middle turbinates from CRSwNP also express elevated levels of IgE 
and ECP, although the mucosa is not prone to form polyps. This inflammation in 
the middle and inferior turbinates can explain why inflammatory levels in nasal 
secretions don’t decrease to the same levels as in healthy controls after surgery. 
The reboot technique is controversial. Removing all mucosa down to the perios-
teum is thought to cause severe complications and scar formation post-operatively. 
In our patients we saw healthy mucosa covering the sinus walls within 4-6 weeks 
post-operatively, and this mucosa showed all elements of normal structured cili-
ated epithelium with activated goblet cells112. It is well known that resection of 
large areas of sinus mucosa often is needed in cases of malignant sinus tumors or 
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inverted papilloma, where appropriate wound healing has been observed114, 115. The 
positive post-operative healing effect in CRSwNP may come from the fact that 
type 2 immune reactions disturb reepithelization14, and the complete removal of 
the sinus mucosa therefore can be regarded as an advantage for wound healing. It 
is also likely that the healing process in our patients is influenced by the treatment 
with doxycycline postoperatively. Doxycycline, a tetracycline antibiotic, is known 
to affect different critical aspects of the wound healing process116, 117. Doxycycline 
is a potent inhibitor of synthesis and effects of matrix metalloproteinases (MMP)118. 
Elevated levels of MMP-9 in the preoperative and postoperative period have been 
shown to be associated with poor wound healing in CRS119. Huvenne et al.  has 
shown improved wound healing in CRS patients undergoing frontal sinus surgery 
when treated with doxycycline releasing stents compared to placebo stents120. 
Doxycycline coated tracheal stents have been shown to reduce tracheal inflam-
mation and fibrosis in a rabbit model121 and doxycycline inhibits staphylococcal 
Exotoxin induced T-cell proliferation and cytokine release122. All patients in our 
study, regardless of treatment with reboot or non-reboot surgery, were treated in 
the same way, hence doxycycline does not likely influence the recurrence rates 
when comparing both groups. In patients with severe CRSwNP, new treatment 
strategies should be considered, including treatment with mAbs and reboot surgery.
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6 CONCLUSIONS
• The inflammation in CRSwNP appears to be widespread involving not 
only polyp tissue by also the seemingly heathy tissue that lines all sinus 
cavities. These results also indicate that the formation of polyps, at least 
in part, is driven by mechanisms not directly related to the type and extent 
of tissue inflammation. 
• A shift towards type 2 inflammation is evident in non-asthmatic, non-
allergic patients with CRS during the past 8-10 years. This swing is more 
pronounced in CRSwNP than in CRSsNP. This indicates that severe CRS 
cases might be more common in the future. 
• Serum periostin, IgE and SE-IgE can be used as biomarkers to identify 
type 2 CRSwNP with reasonable sensitivity and specificity. The levels of 
EBC correlates poorly with type 2 inflammatory markers in nasal polyp 
tissue. However, used together with questions about asthma, allergy and 
AERD they can help identifying the most severe cases in a clinical setting. 
• Dupilumab reduces levels of type 2 inflammation in nasal polyp tissue 
and in nasal secretions demonstrating a local effect on eosinophilic acti-
vation, survival and migration.
• Reboot surgery appears to be superior to a more traditional surgical 
approach when it comes to symptom reduction and increase in quality 
of life in severe cases of CRSwNP. Reboot surgery reduces the type 2 
inflammatory response, 12 months after surgery, in a magnitude well cor-




Kronisk rhinosinuit (CRS) är en inflammation i näsa och bihålor med symtom 
som varar minst 12 veckor. CRS kännetecknas av nästäppa, rinnsnuva, nedsatt lukt 
och smak samt ansiktssmärta. Ungefär var tionde europé drabbas någon gång av 
denna sjukdom, något som orsakar stora kostnader för både individer och samhälle. 
Patienter med CRS besväras även, utöver symtomen i näsan, av andra symtom, 
som sömn- och koncentrationssvårigheter. De upplever också en sänkning av sin 
livskvalitet i paritet med t.ex. hjärtsviktspatienter.
CRS delas upp i sjukdom med och utan näspolyper (CRSwNP respektive CRSsNP). 
Vid båda tillstånden kan den underliggande inflammationen i sin tur delas in i typ 
1 och typ 2. Typ 2-inflammation domineras av eosinofila celler, ses företrädesvis i 
västvärlden och är ofta associerad med astma, medan typ 1 domineras av neutrofila 
celler och är starkt representerad i Asien. Båda typerna kan genom laboratorieun-
dersökningar av nässlemhinna och polyper delas upp i ett flertal undergrupper, s.k. 
endotyper. Vilken endotyp patienten tillhör säger något om hur patienten kommer 
att svara på behandling. 
Traditionellt behandlas CRS med kortisonnässpray och näsköljningar samt vid 
behov kirurgi. Vid svår sjukdom kan de kirurgiska ingreppen bli många. Svår astma 
har sedan några år behandlats med en ny form av läkemedel, monoklonala antik-
roppar, även kallade biologiska läkemedel. Dessa läkemedel riktar sig direkt mot 
enskilda cellers inflammatoriska svar och på så sätt sjukdomens endotyp. Dessa 
monoklonala antikroppar fungerar speciellt bra vid typ 2 astma. De har därför, 
med framgång, nyligen även testas vid CRSwNP av typ 2.
Målet med föreliggande avhandling är att kartlägga inflammationsbiologin bakom 
CRS endotyper, och med detta som utgångspunkt finna lämpliga laboratorieprov 
(biomarkörer) som i kombination med samsjuklighet, som astma och allergi, kan 
ge prognostisk och terapeutisk vägledning. Vidare utvärderas ett nytt kirurgiskt 
angreppssätt (reboot) samt en ny biologisk behandling vid CRSwNP.
Delarbete I och II undersöker om biomarkörer i kombination med samsjuklighet 
kan användas för att förutsäga speciellt svåra former av CRSwNP. Avhandlingen 
lyfter här fram tre blodprov som var och ett för sig, eller i kombination, skulle 
kunna användas för detta ändamål: Periostin, Immunoglobulin E (IgE) och speci-
fika IgE antikroppar mot staphylococcus aureus (SE-IgE). Vi visar också att den 
traditionella markören eosinofiler i blod korrelerar dåligt med typ 2 markörer i 
näspolypvävnad, men att eosinofiler i blod tillsammans med frågor om astma och 
allergi kan hjälpa till att identifiera de svårast sjuka CRS patienterna. I delarbete 
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II visas även att en allt större del av CRS patienterna i Europa övergått från typ 1 
till typ 2, något som tidigare har varit känt i Asien. 
I delarbete III-V undersöks nya behandlingsformer. I delarbete III visas hur en ny 
monoklonal antikropp, Dupilumab, sänker nivåerna av typ 2-markörer i vävnad och 
sekret. Detta tyder på en lokal effekt på de eosinofiler i vävnaden som driver sjukdomen. 
Delarbete IV är en retrospektiv studie, som jämför en ny, mer extensiv, kirurgisk 
metod (reboot) med konventionell kirurgi vid CRSwNP. Vid reboot tas all slemhinna 
i bihålorna bort, inte bara polyper som vid konventionell bihålekirurgi. Patienter 
som genomgått reboot kirurgi hade lägre recidivrisk vid tvåårsuppföljning jämfört 
med patienter som opererats på traditionellt sätt. De beskrev också en mer uttalad 
symtomförbättring än de traditionellt opererade patienterna. I delarbete V visade 
vi att inflammationen vid CRS inte är begränsad till själva polyperna utan omfat-
tar all slemhinna som utkläder bihålorna. Detta förklarar sannolikt varför reboot-
kirurgi, där all slemhinna avlägsnas, minskar risken för återfall. Avslutningsvis 
presenteras data som visar att reboot-kirurgi reducerar inflammationsbilden i 
bihålan på samma sätt som behandling med Dupilumab samt att denna sänkning 
kvarstår 12 månader efter operationen. 
Sammanfattningsvis kastar denna avhandling nytt ljus över patofysiologin vid 
CRSwNP, där ett skifte mot svårare sjukdom ses i Europa. Avhandlingen visar 
att biomarkörer och klinisk karakteristik kan hjälpa till att identifiera de svårast 
sjuka. Den ger även en ökad förståelse för mekanismen bakom behandling med 
monoklonala antikroppar samt introducerar en ny kirurgisk metod och förklarar 
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